Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery
December 20, 2023 06:30 ET
|
Oculis Holding AG
Initiation of the second Phase 3 OPTIMIZE-2 trial with OCS-01 once daily eye drop, follows the recently reported positive OPTIMIZE-1 trial results OPTIMIZE-2 topline readout expected before end of...
Oculis Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema
December 18, 2023 06:30 ET
|
Oculis Holding AG
DIAMOND-1 Phase 3 trial, assessing the efficacy and safety of OCS-01 eye drops following 52 weeks of treatment in Diabetic Macular Edema (DME) patients, was initiated as plannedStage 1 results showed...
Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNFα Licaminlimab (OCS-02) in Dry Eye Disease
December 07, 2023 06:30 ET
|
Oculis Holding AG
Licaminlimab is a novel anti-TNFα biologic eye drop with an established dual mechanism of action, anti-inflammatory and anti-apoptotic, and a potential transformative impact on the treatment of...
Oculis Reports Q3 2023 Financial Results and Provides Company Update
November 15, 2023 06:30 ET
|
Oculis Operations Sarl
Reported lead product candidate OCS-01 eye drop met both primary endpoints in Phase 3 OPTIMIZE trial for inflammation and pain after cataract surgery following positive readout of Stage 1 of the Phase...
Oculis to Present at Upcoming November Investor Conferences
November 08, 2023 06:30 ET
|
Oculis Holding AG
ZUG, Switzerland, and BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...
Oculis to Present a Late-Breaking Abstract at the American Academy of Ophthalmology 2023 Annual Meeting on the Positive Stage 1 Results from Phase 3 DIAMOND Trial for Diabetic Macular Edema
November 01, 2023 06:30 ET
|
Oculis Holding AG
ZUG, Switzerland and BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and...
Positive Phase 3 Stage 1 DIAMOND Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress
October 10, 2023 06:30 ET
|
Oculis Holding AG
OCS-01’s positive results in Stage 1 of the Phase 3 DIAMOND trial for diabetic macular edema (DME) were presented as a late-breaking abstract showing that the trial met primary and secondary endpoints...
Oculis to Present a Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular Edema
October 05, 2023 06:30 ET
|
Oculis Holding AG
ZUG, Switzerland, and BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and...
Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase
September 11, 2023 06:30 ET
|
Oculis Holding AG
Following the achievement of two positive key late-stage clinical milestones on its lead product candidate OCS-01 and recent listing on NASDAQ, Oculis is strengthening its executive leadership team...
Oculis to Present at Upcoming September Investor Conferences
August 30, 2023 06:30 ET
|
Oculis Holding AG
ZUG, Switzerland, and BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...